EP0281579A4 - Co-facteur de prourokinase. - Google Patents

Co-facteur de prourokinase.

Info

Publication number
EP0281579A4
EP0281579A4 EP19870905410 EP87905410A EP0281579A4 EP 0281579 A4 EP0281579 A4 EP 0281579A4 EP 19870905410 EP19870905410 EP 19870905410 EP 87905410 A EP87905410 A EP 87905410A EP 0281579 A4 EP0281579 A4 EP 0281579A4
Authority
EP
European Patent Office
Prior art keywords
pro
cofactor
fibrin
column
affinity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19870905410
Other languages
German (de)
English (en)
Other versions
EP0281579A1 (fr
Inventor
Victor E Gurewich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP0281579A1 publication Critical patent/EP0281579A1/fr
Publication of EP0281579A4 publication Critical patent/EP0281579A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator

Definitions

  • This invention relates to the therapeutic lysis of fibrin blood clots (thrombi) in human patients.
  • urokinase (UK), which is believed to be synthesized in vivo as a single-chain, zymogenic form (pro-UK), which can be converted to the more active two-chain form by a specific proteolytic cleavage.
  • Pro-UK is normally administered by infusion for the lysis of coronary thrombi, in a dosage of 30-60 mg/hr for approximately one hour to achieve thrombus lysis, and then administered for approximately three hours in a dosage of 10-20 mg/hr to prevent re-occlusion.
  • the invention features a method of increasing the efficacy of pro-UK-induced thrombolysis in a human patient to whom pro-UK is administered, the method involving administering to the patient, in addition to the pro-UK, a cofactor of pro-UK and UK, the cofactor being characterized in that a) it has a molecular weight of about 50,000; b) it increases the affinity of pro-UK for fibrin; c) it confers, on the UK generated from pro-UK, affinity for fibrin; and d) it confers, on the UK generated from pro-UK, thrombolyti ⁇ activity which is fib in-dependent.
  • the pro-UK cofactor of the invention because of the above-cited characteristics, can enhance the therapeutic efficacy of pro-UK and thus permit lower dosages to be used.
  • the increased binding affinity for fibrin (of which thrombi are composed) conferred on pro-UK and urokinase by the cofactor of the invention can target the pro-UK and its activated derivative more tightly to the thrombus it is administered to dissolve.
  • the cofactor may enhance specificity by reducing non-specific plasminogen activation, and thus deleterious, non-specific effects are reduced.
  • the clearance time (T. /2 ) of the pro-UK cofactor complex may be greater than that of pro-UK alone.
  • the fibrin affinity of pro-UK or UK and cofactor-bound pro-UK (cfb-pro-UK) or UK was compared by affinity chromatography on a fibrin/Celite column prepared by mixing Celite (Fischer Scientific Co.) with 2 percent human fibrinogen (Kabi) in 25 ml buffer (0.05M NaP0 4 , 0.1 M NaCl, ImM EDTA, pH 7.4) and then precipitating a fibrin matrix onto the Celite by slow addition of 100 units of thrombin (Parke Davis) with constant stirring.
  • the fibrin-matrix was packed on a column and washed with 10 volumes of equilibration buffer (0.05 M NaP0 4 , 0.3 M NaCl, 1 M EDTA, pH 7.4).
  • pro-UK or UK purified from human kidney cell culture
  • cfb-pro-UK or UK were loaded on the column, run in equilibration buffer, and fractions collected and assayed for fibrinolytic activity in a standard fibrin plate assay.
  • Cfb-pro-UK or cfb-UK in urine when loaded on the column, bound to a significantly greater degree to the fibrin affinity column than pro-UK alone or UK alone.
  • the thrombolyti ⁇ activity of cfb-pro-UK and of cfb-UK remained bound until an elution buffer containing 0.2M arginine was run on the column.
  • the UK-cofactor complex in concentrated urine is devoid of amidolytic activity.
  • the cofactor of the invention is a naturally occurring compound which can be isolated from human urine or plasma. It is believed to be identical to the Mr ⁇ 50,000 urokinase inhibitor purified from urine by Stump et al. JBC 261:12759-12766, 1986, hereby incorporated by reference.
  • the cofactor can be isolated and produced by itself and then mixed with pro-UK to form a complex which will bind more tightly to fibrin than pro-UK alone.
  • the cofactor can be isolated from urine or plasma by the published method for isolating the inhibitor (Stump et al., id.).
  • the procedure for isolating the compound from urine given in Stump et al. is as follows. Fresh human urine is collected on benzamidine, cooled to 4° C, and adjusted to pH 7.5 with NaOH and cent ifuged at 6000 X g for 30 min at 4° C. The supernatant is applied to a 10 X 15-cm column of zinc chelate-Sepharose at a flow rate of 500 ml/h.
  • the column is washed with 1 liter of 0.3 M NaCL, 0.02 M NaH 2 P0 4 buffer, pH 7.5, containing 5 mM benzamidine, stirred, and washed with an additional 2 liters of the same buffer.
  • the column is then eluted with the same buffer, containing 0.05 M imidazole, and 20-ml fractions are collected.
  • Fractions containing protein are pooled, adjusted to pH 7.5 with 1 M HCl, and applied directly at a flow rate of 20 ml/h to a 2 X 6.5-cm column of concanavalin A-Sepharose equilibrated with 0.15 M NaCl, 0.02 M NaH 2 P0 4 buffer, pH 7.5, containing 5 mM benzamidine.
  • the column is washed first with 100 ml of equilibration buffer and then with equilibration buffer without benzamidine until the absorbance at 280 nm is below 0.05 (5 to 10 column volumes).
  • the column is then eluted with 0.15 M NaCl, 0.02 M NaH 2 P0 4 buffer, pH 7.5, containing 0.5 M methyl- ⁇ -D-glucopyranoside at a flow rate of 10 ml/h, collecting fractions of 5 ml.
  • Fractions containing protein are pooled and dialyzed against 0.02 M NaCl, 0.02M aH 2 P0 4 buffer, pH 6.8, to a conductance equal to that of the dialysis buffer.
  • the dialyzed sample is then applied to a 0.9 X 13-cm column of SP-Sephadex C-50, equilibrated with dialysis buffer, at a flow rate of 5 ml/h.
  • the column is washed with the same buffer until the absorbance at 280 nm is less than 0.05 and then a linear 60-ml NaCl gradient from Q.02 to 0.5 M is applied.
  • Two-ml fractions, containing the inhibitor/cofactor compound, as measured by ELISA, are pooled and concentrated to 2 ml by dialysis against solid PEG 20,000. This sample is dialyzed against 1 liter of 0.3 M NaCl, 0.02 M NaH 2 P0 4 buffer, pH 7.5, and applied to a 1.5 X 90-cm column of Sephadex G-100 superfine at a flow rate of 4 ml/h. Two-ml fractions are assayed for inhibitor/cofactor, and enriched fractions are pooled.
  • the first step chro atography of cooled, pH-adjusted, human urine on zinc chelate-Sepharose results in 75% absorption of inhibitor/cofactor. Elution with imidazole results in a recovery of 50% of the original protein with a 30-fold volume reduction and a 10-fold purification. Direct application of this eluate to concanavalin A-Sepharose gives 90% absorption of inhibitor/cofactor whereas free urokinase is not bound. Elution with 0.5 M methyl- ⁇ -D-glucopyranoside results in a recovery of 43 percent of the original starting inhibitor/cofactor, with an additional 4-fold purification and 10-fold volume reduction.
  • the cofactor and pro-UK are administered together, either as a complex or separately so that the complex forms in vivo, to dissolve thrombi in patients who have recently suffered a thromboembolic event (e.g., coronary thrombi, deep vein thrombi, pulmonary emboli, and cerebral and peripheral vascular thrombi).
  • Pro-UK and the cofactor are admixed with a pharmaceutically acceptable carrier substance, e.g., saline, and administered intravenously.
  • a pharmaceutically acceptable carrier substance e.g., saline
  • lyophilized pro-UK and a molar equivalent of lyophilized cofactor are mixed together after solubilization in saline and placed in the chamber of a syringe, which is used to inject the resulting cfb-pro-UK bolus into the patient intravenously.
  • lyophilized pro-UK and a molar equivalent of lyophilized cofactor dissolved in saline are infused at the same time, together or via separate infusion lines, intravenously over a period of about 1 hour, followed by intravenous infusion of about 5 mg/hr pro-UK and a molar equivalent of cofactor over a period of about three more hours.
  • Example 4 For infusion treatment for the slow lysis of deep vein thrombi, about 2-5 mg/hr of lyophilized pro-UK and a molar equivalent of lyophilized pro-UK dissolved in saline are infused, at the same time, together or via separate infusion lines, intravenously over a period of about 12-24 hours.
  • Example 5 For infusion treatment for the slow lysis of deep vein thrombi, about 2-5 mg/hr of lyophilized pro-UK and a molar equivalent of lyophilized pro-UK dissolved in saline are infused, at the same time, together or via separate infusion lines, intravenously over a period of about 12-24 hours.
  • Example 5 For infusion treatment for the slow lysis of deep vein thrombi, about 2-5 mg/hr of lyophilized pro-UK and a molar equivalent of lyophilized pro-UK dissolved in saline are infused, at the same time, together or via separate infusion lines, intravenously over a period of
  • Pro-UK and cofactor in a 1:1 molar ratio are dissolved together in saline and the solution then lyophilized to provide lyophilized cfb-pro-UK which is easily transported and stored prior to reconstitution, with saline, and use.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Procédé permettant d'accroître l'efficacité d'une thrombolyse induite par une prourokinase chez un patient auquel une prourokinase est administrée. Ce procédé consiste à administrer au patient, en plus de la prourokinase, un co-facteur de prourokinase et d'urokinase, le co-facteur se caractérisant en ce que a) il présente un poids moléculaire de 50 000 environ; b) il accroît l'affinité de la prourokinase pour la fibrine; c) il confère à l'urokinase produite par la prourokinase une affinité pour la fibrine; d) il confère à l'urokinase produite par la prourokinase une activité thrombolytique dépendant de la fibrine.
EP19870905410 1986-08-12 1987-08-11 Co-facteur de prourokinase. Withdrawn EP0281579A4 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US89588486A 1986-08-12 1986-08-12
US895884 1986-08-12
US883787A 1987-01-30 1987-01-30
US8837 1987-01-30

Publications (2)

Publication Number Publication Date
EP0281579A1 EP0281579A1 (fr) 1988-09-14
EP0281579A4 true EP0281579A4 (fr) 1989-01-19

Family

ID=26678686

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19870905410 Withdrawn EP0281579A4 (fr) 1986-08-12 1987-08-11 Co-facteur de prourokinase.

Country Status (2)

Country Link
EP (1) EP0281579A4 (fr)
WO (1) WO1988001175A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0181596A2 (fr) * 1984-11-05 1986-05-21 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Procédé de préparation d'un complexe d'urokinase
WO1986003973A1 (fr) * 1985-01-14 1986-07-17 Terumo Kabushiki Kaisha Complexe d'urokinase fibrinophile et procede de preparation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029767A (en) * 1971-09-24 1977-06-14 Choay S.A. Pharmaceutical compositions of stable urokinase-heparin complexes and methods for use thereof
US4106992A (en) * 1971-09-24 1978-08-15 Choay S.A. Purification of urokinase

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0181596A2 (fr) * 1984-11-05 1986-05-21 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Procédé de préparation d'un complexe d'urokinase
WO1986003973A1 (fr) * 1985-01-14 1986-07-17 Terumo Kabushiki Kaisha Complexe d'urokinase fibrinophile et procede de preparation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 105, 1986, page 263, abstract no. 2687q, Columbus, Ohio, US; R. PANNELL et al.: "Pro-urokinase: a study of its stability in plasma and of a mechanism for its selective fibrinolytic effect", & BLOOD, 1986, 67(5), 1215-23 *
See also references of WO8801175A1 *

Also Published As

Publication number Publication date
WO1988001175A1 (fr) 1988-02-25
EP0281579A1 (fr) 1988-09-14

Similar Documents

Publication Publication Date Title
US4752603A (en) Plasminogen activator and pharmaceutical composition having thrombolytic activity
JP2631645B2 (ja) 新規化合物、その製法及びそれを含む医薬組成物
JP3032085B2 (ja) プロテインｃを含有し血栓溶解活性を有する非経口投与が可能な薬剤
WO1990014102A1 (fr) Complexes cibles sur un thrombus constitues d'un activateur de plasminogene et de fragments de fibrine
JP2764264B2 (ja) 線溶活性増強剤
EP0395918A2 (fr) Complexe d'activateur de plasminogène de pro-urokinase pure liée de manière covalente par un pont disulfure à de la sérum albumine humaine
AU658881B2 (en) Use of protein C or activated protein C
AU606582B2 (en) Methods for the recovery of tissue plasminogen activator
EP0804228B1 (fr) Médicament contenant le peptide d'activation de la proteine C
US6001355A (en) Pro-tPA for the treatment of thrombosis, embolism and related conditions
EP0218479A2 (fr) Réactif et procédé
US5830467A (en) Pharmaceutical preparation containing protein C and a thrombolytically active substance
JPS61267524A (ja) フィブリン親和性ウロキナーゼ複合体含有血栓溶解剤
WO1988001175A1 (fr) Co-facteur de prourokinase
JPS59118717A (ja) プラスミノーゲン活性化剤
US20010046495A1 (en) Use of cross-linked, covalently bound urokinase plasminogen activator (scuPAR)-urokinase plasminogen activator receptor (suPAR) complex as a fibrinolytic agent
US5342616A (en) Method of administering tissue plasminogen activator
US20020031518A1 (en) Plasminogen fragment having activity to inhibit tumor metastasis and growth and process for preparing same technical field
CA2141642A1 (fr) Fragments de facteur ix de stabilisation des thrombocytes, leur preparation et leur utilisation et medicaments contenant ces fragments
CA1338551C (fr) Medicament a base de tpa pour troubles thrombotiques
US5234686A (en) Human tissue plasminogen activator consisting essentially of t-PA residues to 160 to 527, pharmaceutical compositions and methods of treatment
CA1333163C (fr) Methodes d'isolement de l'activateur tissulaire du plasminogene
JP3806471B2 (ja) 腫瘍転移増殖抑制効果を有するプラスミノーゲン断片および該断片の調製方法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19880505

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19890119

17Q First examination report despatched

Effective date: 19910527

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19911008